ArticleMetabolomics : Official journal of the Metabolomic Society2026
Synergistic lipase inhibition by Garcinia parvifolia metabolites: a
Article in Metabolomics : Official journal of the Metabolomic Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe rising prevalence of obesity and metabolic disorders has intensified the demand for sustainable, plant-based functional ingredients for weight management. Garcinia parvifolia, an underutilized tropical fruit native to Malaysian Borneo, represents a promising natural source of anti-obesity compounds.
objectivesThis study aimed to decipher the complex, ligand interactions responsible for pancreatic lipase inhibition in G. parvifolia using a multi-disciplinary metabolomics-driven approach.
methodsExtracts of varying polarities (70% ethanol, acetone, chloroform, and hexane) were analyzed using ¹H NMR-based metabolomics, in vitro p-nitrophenyl butyrate (p-NPB) lipase assays, and in silico molecular docking.
resultsThe results demonstrated that solvent polarity critically dictates chemical diversity, with the 70% ethanol extract yielding the highest metabolite abundance and the strongest lipase inhibitory activity (IC₅₀ = 85.3 µg/mL). Multivariate data analyses, including Principal Component Analysis (PCA) and Partial Least Squares (PLS), revealed that this bioactivity is not driven by a single isolated compound, but rather by a synergistic combination of polar phenolic and aromatic metabolites, alongside supportive amino and organic acids. Molecular docking validated the inhibitory potential of key annotated metabolites, demonstrating that compounds such as catechin, β-sitosterol, and β-caryophyllene interact with the enzyme via reversible hydrogen bonding, van der Waals forces, and hydrophobic interactions, exhibiting binding affinities of - 6.09, - 6.34, and - 5.19 kcal/mol, respectively.
conclusionThese findings establish G. parvifolia as a viable, sustainable, and multi-targeted plant-based alternative to synthetic fat blockers. Its integration into functional foods and anti-obesity nutraceutical formulations offers significant potential for advancing preventive and personalized nutrition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.